Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies 
Asian Currencies Steady as Fed Delivers Hawkish Rate Cut; Aussie and Rupee Under Pressure 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
China’s Small Bank Consolidation Struggles as Profits Fall and Risks Persist 
Dollar Struggles as Markets Eye Key Central Bank Decisions and Global Rate Outlooks 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
JW Pharmaceutical will use the zebrafish to develop new drugs and expand indications of its drug candidates.
To expedite the process, the South Korean drug developer has inked a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institute that specializes in zebrafish models.
Zefit will provide disease-specific zebrafish models using gene editing technology and a drug screening platform.
Zebrafish, a tropical fish species whose genetic structure is more than 80 percent similar to humans, is increasingly being used as a non-clinical intermediary research model.
Zebrafish can replace mammalian experiments, according to Zefit.
Conducting experiments with zebrafish can bring down costs to about one-tenth of those for mammals.
JW Pharmaceutica plans to use zebrafish to bridge the gap between non-clinical and clinical research.
Zebrafish experiments can be 91 percent similar to those conducted with mammals.
According to Shin Jun-nyeong, CEO of Zefit, Interest in zebrafish is increasing among regulatory agencies such as the US Food and Drug Administration (FDA).
